Last 7 days
-11.4%
Last 30 days
-21.4%
Last 90 days
5.0%
Trailing 12 Months
-48.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 72.9M | 0 | 0 | 0 |
2023 | 81.2M | 80.6M | 79.2M | 73.6M |
2022 | 91.6M | 89.4M | 86.2M | 82.1M |
2021 | 94.2M | 97.1M | 97.1M | 93.0M |
2020 | 175.9M | 150.2M | 122.5M | 101.6M |
2019 | 234.0M | 221.1M | 205.2M | 187.9M |
2018 | 165.6M | 215.3M | 206.6M | 238.4M |
2017 | 46.2M | 39.7M | 102.8M | 130.5M |
2016 | 87.5M | 89.8M | 88.3M | 50.2M |
2015 | 179.6M | 149.1M | 160.9M | 131.8M |
2014 | 6.1M | 46.5M | 47.7M | 124.3M |
2013 | 36.9M | 34.5M | 32.1M | 5.1M |
2012 | 0 | 0 | 41.7M | 39.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 26, 2024 | gardiner nathaniel s. | acquired | 46,631 | 8.99 | 5,187 | chief legal officer |
Feb 12, 2024 | luu brendan | sold (taxes) | -12,074 | 12.41 | -973 | chief business officer |
Feb 12, 2024 | kieffer tara lynn | acquired | - | - | 3,320 | chief product strategy officer |
Feb 12, 2024 | luly jay r. | sold (taxes) | -19,657 | 12.41 | -1,584 | president and ceo |
Feb 12, 2024 | mellett paul j | sold (taxes) | -12,074 | 12.41 | -973 | chief fin. & admin officer |
Feb 12, 2024 | gardiner nathaniel s. | sold (taxes) | -12,074 | 12.41 | -973 | chief legal officer |
Feb 12, 2024 | luly jay r. | acquired | - | - | 5,400 | president and ceo |
Feb 12, 2024 | luu brendan | acquired | - | - | 3,320 | chief business officer |
Feb 12, 2024 | or yat sun | acquired | - | - | 3,680 | chief scientific officer |
Feb 12, 2024 | gardiner nathaniel s. | acquired | - | - | 3,320 | chief legal officer |
Which funds bought or sold ENTA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 10, 2024 | Clearstead Trust, LLC | unchanged | - | 40,765 | 88,418 | 0.02% |
May 10, 2024 | Covestor Ltd | reduced | -20.00 | - | - | -% |
May 10, 2024 | PNC Financial Services Group, Inc. | added | 905 | 35,560 | 37,574 | -% |
May 10, 2024 | VANGUARD GROUP INC | added | 7.49 | 16,784,700 | 33,664,200 | -% |
May 10, 2024 | ACADIAN ASSET MANAGEMENT LLC | added | 1.3 | 6,980,000 | 14,906,000 | 0.05% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 303 | 376,776 | 434,910 | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | added | 2,590 | 5,065 | 5,168 | -% |
May 10, 2024 | BlackRock Inc. | reduced | -4.94 | 13,904,300 | 32,109,900 | -% |
May 10, 2024 | JPMORGAN CHASE & CO | reduced | -8.47 | 991,076 | 2,410,300 | -% |
May 10, 2024 | CORNERCAP INVESTMENT COUNSEL INC | added | 1.84 | 113,312 | 240,686 | 0.04% |
Unveiling Enanta Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Enanta Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.2B | 6.8B | -8.07 | 7.03 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.0B | 2.0B | -57.12 | 9.47 | ||||
BMRN | 15.3B | 2.5B | 74.39 | 6.18 | ||||
INCY | 12.9B | 3.8B | 17.35 | 3.43 | ||||
MID-CAP | ||||||||
BBIO | 5.3B | 107.9M | -9.76 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.51 | 9.96 | ||||
AXSM | 3.6B | 251.0M | -12.12 | 14.31 | ||||
ARWR | 2.7B | 240.7M | -5.82 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.5K | 3.08 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.44 | 4.66 | ||||
NVAX | 1.8B | 996.6M | -4.62 | 1.85 | ||||
CRBP | 458.7M | 881.7K | -13.59 | 481.06 | ||||
INO | 294.6M | 4.9M | -2.36 | 60.54 | ||||
IBIO | 15.6M | 2.1M | -0.67 | 7.61 |
Enanta Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -5.3% | 17,054,000 | 18,003,000 | 18,932,000 | 18,892,000 | 17,795,000 | 23,585,000 | 20,317,000 | 19,479,000 | 18,716,000 | 27,648,000 | 23,575,000 | 21,624,000 | 20,132,000 | 31,743,000 | 23,631,000 | 18,653,000 | 27,619,000 | 52,570,000 | 51,313,000 | 44,367,000 | 39,631,000 |
Costs and Expenses | -5.8% | 49,820,000 | 52,889,000 | 49,962,000 | 55,605,000 | 57,246,000 | 53,598,000 | 47,365,000 | 52,019,000 | 52,563,000 | 58,057,000 | 57,302,000 | 55,471,000 | 49,832,000 | 44,042,000 | 43,414,000 | 41,505,000 | 39,494,000 | 39,699,000 | 44,882,000 | 40,612,000 | 40,935,000 |
S&GA Expenses | -100.0% | - | 16,518,000 | 13,795,000 | 12,618,000 | 13,778,000 | 12,696,000 | 12,569,000 | 12,929,000 | 10,476,000 | 9,508,000 | 8,356,000 | 8,477,000 | 8,326,000 | 7,377,000 | 6,728,000 | 6,823,000 | 6,884,000 | 6,921,000 | 6,163,000 | 6,151,000 | 6,780,000 |
R&D Expenses | -2.2% | 35,585,000 | 36,371,000 | 36,167,000 | 42,987,000 | 43,468,000 | 40,902,000 | 34,796,000 | 39,090,000 | 42,087,000 | 48,549,000 | 48,946,000 | 46,994,000 | 41,506,000 | 36,665,000 | 36,686,000 | 34,682,000 | 32,610,000 | 32,778,000 | 38,719,000 | 34,461,000 | 34,155,000 |
EBITDA Margin | 6.0% | -1.59 | -1.70 | -1.56 | -1.53 | -1.51 | -1.44 | -1.38 | -1.41 | -1.39 | -1.32 | -1.07 | -0.92 | - | - | - | - | - | - | - | - | - |
Interest Expenses | -25.5% | 2,563,000 | 3,441,000 | 3,151,000 | 1,997,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | 41.6% | -363,000 | -622,000 | -1,410,000 | 4,221,000 | 44,000 | -34,000 | 32,000 | -447,000 | - | -36,000 | -15,905,000 | -9,384,000 | 7,110,000 | -3,294,000 | 10,707,000 | -7,142,000 | -3,920,000 | 1,504,000 | -486,000 | -866,000 | -3,204,000 |
Earnings Before Taxes | 7.4% | -31,520,000 | -34,029,000 | -29,517,000 | -34,844,000 | -37,614,000 | -29,020,000 | -26,316,000 | -32,147,000 | -33,592,000 | -30,151,000 | -33,394,000 | -33,408,000 | -29,155,000 | -11,622,000 | -18,634,000 | -21,407,000 | -9,925,000 | 14,947,000 | 8,705,000 | 6,170,000 | 941,000 |
EBT Margin | 3.5% | -1.78 | -1.85 | -1.65 | -1.59 | -1.54 | -1.47 | -1.42 | -1.45 | -1.43 | -1.36 | -1.11 | -0.96 | - | - | - | - | - | - | - | - | - |
Net Income | 6.7% | -31,157,000 | -33,407,000 | -28,107,000 | -39,065,000 | -37,658,000 | -28,986,000 | -26,348,000 | -31,700,000 | -33,592,000 | -30,115,000 | -24,599,000 | -24,024,000 | -22,045,000 | -8,328,000 | -29,341,000 | -14,265,000 | -6,005,000 | 13,443,000 | 9,191,000 | 7,036,000 | 4,145,000 |
Net Income Margin | 3.7% | -1.81 | -1.88 | -1.69 | -1.64 | -1.54 | -1.47 | -1.41 | -1.34 | -1.23 | -1.08 | -0.81 | -0.86 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -17.4% | -30,269,000 | -25,775,000 | -22,970,000 | -34,279,000 | -16,166,000 | -38,797,000 | -16,971,000 | -29,853,000 | -26,449,000 | -13,634,000 | -21,054,000 | -29,905,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -3.5% | 414 | 428 | 462 | 495 | 326 | 348 | 375 | 385 | 407 | 441 | 439 | 450 | 468 | 481 | 486 | 512 | 514 | 511 | 490 | 473 | 462 |
Current Assets | -10.1% | 351 | 390 | 423 | 448 | 271 | 284 | 312 | 313 | 342 | 327 | 319 | 321 | 428 | 446 | 437 | 413 | 403 | 441 | 402 | 451 | 424 |
Cash Equivalents | 59.1% | 64.00 | 40.00 | 85.00 | 95.00 | 73.00 | 42.00 | 44.00 | 28.00 | 41.00 | 99.00 | 57.00 | 5.00 | 77.00 | 55.00 | 87.00 | 100 | 74.00 | 28.00 | 51.00 | 94.00 | 106 |
Net PPE | 27.7% | 15.00 | 12.00 | 12.00 | 12.00 | 11.00 | 9.00 | 6.00 | 5.00 | 5.00 | 5.00 | 6.00 | 7.00 | 7.00 | 8.00 | 9.00 | 9.00 | 10.00 | 10.00 | 11.00 | 11.00 | 11.00 |
Liabilities | 4.6% | 247 | 237 | 246 | 257 | 57.00 | 47.00 | 54.00 | 47.00 | 48.00 | 56.00 | 39.00 | 33.00 | 32.00 | 29.00 | 31.00 | 31.00 | 28.00 | 29.00 | 27.00 | 25.00 | 25.00 |
Current Liabilities | -12.5% | 55.00 | 62.00 | 63.00 | 68.00 | 32.00 | 23.00 | 30.00 | 23.00 | 31.00 | 38.00 | 36.00 | 29.00 | 27.00 | 23.00 | 24.00 | 24.00 | 20.00 | 19.00 | 23.00 | 21.00 | 20.00 |
Shareholder's Equity | -13.4% | 166 | 192 | 217 | 238 | 269 | 301 | 321 | 338 | 359 | 384 | 399 | 418 | 436 | 452 | 456 | 481 | 486 | 482 | 462 | 448 | 436 |
Retained Earnings | -13.0% | -271 | -240 | -206 | -178 | -139 | -102 | -73.18 | -46.83 | -15.13 | 18.00 | 49.00 | 73.00 | 97.00 | 119 | 128 | 157 | 171 | 177 | 164 | 155 | 148 |
Additional Paid-In Capital | 1.3% | 438 | 433 | 425 | 418 | 411 | 405 | 398 | 388 | 377 | 367 | 351 | 345 | 339 | 332 | 327 | 322 | 314 | 305 | 298 | 293 | 289 |
Shares Outstanding | 0.1% | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 20.00 | 20.00 | 20.00 | 20.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | 800 | - | - | - | 1,262 | - | - | - | 865 | - | - | - | 754 | - | - | - | 1,408 |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -14.5% | -28,601 | -24,988 | -21,602 | -32,128 | -13,783 | -35,641 | -15,534 | -29,602 | -26,375 | -13,271 | -21,021 | -29,506 | -4,579 | -14,890 | -15,461 | -4,488 | 14,674 | 12,363 | 8,545 | 2,533 | 30,086 |
Share Based Compensation | -31.3% | 5,561 | 8,099 | 6,716 | 6,998 | 7,363 | 7,139 | 6,833 | 7,603 | 6,471 | 6,062 | 5,353 | 5,475 | 5,280 | 4,883 | 4,745 | 4,754 | 4,978 | 5,098 | 4,512 | 4,164 | 4,707 |
Cashflow From Investing | 546.9% | 58,624 | -13,117 | 11,836 | -145,748 | 46,765 | 33,569 | 28,231 | 16,220 | -35,055 | 45,501 | 72,683 | -43,705 | 25,458 | -17,445 | 2,504 | 26,779 | 27,748 | -37,201 | -52,208 | -14,847 | 1,322 |
Cashflow From Financing | 12.7% | -6,414 | -7,350 | -23.00 | 199,875 | -2,027 | 301 | 2,930 | 4,120 | 3,351 | 9,632 | 943 | 686 | 1,152 | 299 | 233 | 3,226 | 4,358 | 1,166 | 687 | 490 | 257 |
Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
Total revenue | $ 17,054 | $ 17,795 | $ 35,057 | $ 41,380 |
Operating expenses: | ||||
Research and development | 35,585 | 43,468 | 71,956 | 84,370 |
General and administrative | 14,235 | 13,778 | 30,753 | 26,474 |
Total operating expenses | 49,820 | 57,246 | 102,709 | 110,844 |
Loss from operations | (32,766) | (39,451) | (67,652) | (69,464) |
Other income (expense): | ||||
Interest expense | (2,563) | 0 | (6,004) | 0 |
Interest and investment income, net | 3,809 | 1,837 | 8,107 | 2,830 |
Total other income, net | 1,246 | 1,837 | 2,103 | 2,830 |
Loss before income taxes | (31,520) | (37,614) | (65,549) | (66,634) |
Income tax benefit (expense) | 363 | (44) | 985 | (10) |
Net loss | $ (31,157) | $ (37,658) | $ (64,564) | $ (66,644) |
Net loss per share: | ||||
Basic | $ (1.47) | $ (1.79) | $ (3.06) | $ (3.19) |
Diluted | $ (1.47) | $ (1.79) | $ (3.06) | $ (3.19) |
Weighted average shares outstanding: | ||||
Basic | 21,167 | 21,035 | 21,128 | 20,882 |
Diluted | 21,167 | 21,035 | 21,128 | 20,882 |
Royalty [Member] | ||||
Total revenue | $ 17,054 | $ 17,795 | $ 35,057 | $ 40,380 |
License [Member] | ||||
Total revenue | $ 0 | $ 0 | $ 0 | $ 1,000 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Sep. 30, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 63,542 | $ 85,388 |
Short-term marketable securities | 236,768 | 284,522 |
Accounts receivable | 7,756 | 8,614 |
Prepaid expenses and other current assets | 10,932 | 13,263 |
Income tax receivable | 32,031 | 31,004 |
Total current assets | 351,029 | 422,791 |
Property and equipment, net | 15,479 | 11,919 |
Operating lease, right-of-use assets | 42,894 | 22,794 |
Restricted cash | 3,968 | 3,968 |
Other long-term assets | 187 | 803 |
Total assets | 413,557 | 462,275 |
Current liabilities: | ||
Accounts payable | 6,726 | 4,097 |
Accrued expenses and other current liabilities | 10,630 | 18,339 |
Liability related to the sale of future royalties | 33,671 | 35,076 |
Operating lease liabilities | 3,581 | 5,275 |
Total current liabilities | 54,608 | 62,787 |
Liability related to the sale of future royalties, net of current portion | 147,776 | 159,429 |
Operating lease liabilities, net of current portion | 43,412 | 21,238 |
Series 1 nonconvertible preferred stock | 1,423 | 1,423 |
Other long-term liabilities | 224 | 663 |
Total liabilities | 247,443 | 245,540 |
Commitments and contingencies (Note 11) | ||
Stockholders' equity: | ||
Common stock; $0.01 par value per share, 100,000 shares authorized; 21,179 and 21,059 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively | 212 | 211 |
Additional paid-in capital | 438,128 | 424,693 |
Accumulated other comprehensive loss | (667) | (1,174) |
Accumulated deficit | (271,559) | (206,995) |
Total stockholders' equity | 166,114 | 216,735 |
Total liabilities and stockholders' equity | $ 413,557 | $ 462,275 |
 | Dr. Jay R. Luly Ph.D. |
---|---|
 | enanta.com |
 | Biotechnology |
 | 160 |